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Abstract
The mechanisms of free fatty acid-induced lipoapoptosis are incompletely understood. Here we
demonstrate that Mcl-1, an anti-apoptotic member of the Bcl-2 family, was rapidly degraded in
hepatocytes in response to palmitate and stearate by a proteasome-dependent pathway.
Overexpression of a ubiquitin-resistant Mcl-1 mutant in Huh-7 cells attenuated palmitate-mediated
Mcl-1 loss and lipoapoptosis; conversely, short hairpin RNA-targeted knockdown of Mcl-1 sensitized
these cells to lipoapoptosis. Palmitate-induced Mcl-1 degradation was attenuated by the novel protein
kinase C (PKC) inhibitor rottlerin. Of the two human novel PKC isozymes, PKCį and PKCǇ, only
activation of PKCǇ was observed by phospho-immunoblot analysis. As compared with Jurkat cells, a
smaller PKCǇ polypeptide and mRNA were expressed in hepatocytes consistent with an alternative
splice variant. Short hairpin RNA-mediated knockdown of PKCǇ reduced Mcl-1 degradation and
lipoapoptosis. Likewise, genetic deletion of PkcǇ also attenuated Mcl-1 degradation and cytotoxicity
by palmitate in primary hepatocytes. During treatment with palmitate, rottlerin inhibited
phosphorylation of Mcl-1 at Ser , a phosphorylation site previously implicated in Mcl-1 turnover.
Consistent with these results, an Mcl-1 S159A mutant was resistant to degradation and improved cell
survival during palmitate treatment. Collectively, these results implicate PKCǇ-dependent
destabilization of Mcl-1 as a mechanism contributing to hepatocyte lipoapoptosis.
Current evidence suggests that hepatic steatosis is present in up to 30% of the American population
(1). A subset of these individuals develop severe hepatic lipotoxicity, a syndrome referred to as NASH
(2), which can progress to cirrhosis and its chronic sequela (3, 4). A major risk factor for hepatic
lipotoxicity is insulin resistance (5–7), resulting in excessive lipolysis within peripheral adipose tissue
with release of high levels of free fatty acids (FFA) to the circulation. Circulating FFA are taken up by
the liver via fatty acid transporter 5 and CD36 (8–10), and the bulk of hepatic neutral fat is derived
from re-esterification of circulating FFA (8). Current concepts indicate that FFA, and not their
esterified product (triglyceride), mediate hepatic lipotoxicity (11, 12). Elevated serum FFA correlate
with liver disease severity (13–15), and therapies that enhance insulin sensitivity ameliorate hepatic
lipotoxicity, in part, by decreasing plasma FFA (16). Hepatic FFA also accumulate in experimental
steatohepatitis, further supporting a role for these nutrients in hepatic lipotoxicity (17). Saturated FFA
are more strongly implicated in hepatic lipotoxicity than unsaturated FFA (18, 19). Saturated FFA
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induce hepatocyte apoptosis (20, 21), a cardinal feature of nonalcoholic fatty liver disease (22), and
serum biomarkers of apoptosis are useful for identifying hepatic lipotoxicity (23). Thus, FFA-mediated
lipotoxicity occurs, in part, by apoptosis.
Apoptosis is regulated by members of the Bcl-2 protein family (24). These proteins can be categorized
into three subsets as follows: the guardians or anti-apoptotic members of this family, which include
Bcl-2, A1, Mcl-1, Bcl-x , and Bcl-w; the multidomain executioners or proapoptotic members of this
family, which include Bax and Bak; and the messengers or biosensors of cell death, which share only
the third Bcl-2 homology domain and are referred to as BH3-only proteins. This last group of proteins
includes Bid, Bim, Bmf, Puma, Noxa, Hrk, Bad, and Bik. We have previously reported that cytotoxic
FFA induce Bim expression by a FoxO3a-dependent mechanism that contributes, in part, to
lipoapoptosis by activating Bax (20, 21). However, Bax activation can be held in check by
anti-apoptotic members of the Bcl-2 family suggesting their function may also be dysregulated during
FFA-mediated cytotoxicity.
Bcl-2 is not expressed in hepatocytes at the protein level (25), whereas Bcl-w and Bfl-1/A1 knock-out
mice have no liver phenotype (26–28). However, both potent anti-apoptotic proteins Bcl-x  and Mcl-1
are expressed by hepatocytes and exhibit a liver phenotype in knock-out mice (29, 30), whereas
up-regulation of Mcl-1 renders hepatocytes resistant to apoptosis (31–33). It has also been posited
that cellular elimination of Mcl-1 is a critical step in certain proapoptotic cascades (34, 35). Mcl-1 is
unique among Bcl-2 proteins in that it has a short half-life, 30–120 min in most cell types, due to the
presence of two sequences rich in proline, glutamic acid, serine, and threonine, which target the
protein for rapid degradation by the proteasome (36). Proteasomal degradation of Mcl-1 is promoted
by ubiquitination, which in turn is regulated by various kinase cascades (36). Despite its potential
importance, a role for Mcl-1 in regulating hepatocyte FFA-mediated lipoapoptosis remains
unexplored.
Given that FFA induce insulin resistance (37), the kinases potentially regulating lipoapoptosis are
likely those also identified in insulin resistance syndromes, especially the novel PKC isoforms PKCį
and PKCǇ (38). The novel PKC isoforms are activated by diacylglycerol, which rises in the presence of
FFA (39–41), and diacylglycerol levels are significantly increased in NASH (42). A role for PKCį in
apoptosis has not been described. PKCǇ has recently been shown to be activated by endoplasmic
reticulum stress in liver cells (43) and lipids in vivo (44, 45). Furthermore, PKCǇ has also been
implicated in apoptosis of Jurkat cells, neuroblastoma cells, and myeloid leukemia cells (46, 47).
However, neither its role in mediating lipoapoptosis nor modulating levels/activity of Bcl-2 proteins
has been examined.
This study addresses the role of Mcl-1 and PKCǇ in FFA-induced lipoapoptosis. We identify a pathway
that involves PKCǇ-dependent proteasomal degradation of Mcl-1. Using inhibitors of various steps
along this pathway, along with Mcl-1 mutants that are resistant to proteasomal degradation or Ser
phosphorylation, our studies implicate Mcl-1 degradation via a PKCǇ-dependent process as a critical
step in lipoapoptosis.
EXPERIMENTAL PROCEDURES
Isopropyl alcohol and bovine serum albumin were from Sigma. Rottlerin (a novel PKC
inhibitor) and glycogen synthase kinase-3ǃ (GSK-3ǃ) inhibitor IX were from Calbiochem. Z-VAD-fmk
was from Enzyme Systems (Livermore, CA).
Huh-7 cells, a human hepatoma cell line, and primary mouse hepatocytes were cultured in
Dulbecco's modified Eagle's medium containing high glucose (25 mM), 100,000 units/liter penicillin,
100 mg/liter streptomycin, and 10% (v/v) heat-inactivated fetal bovine serum. Mouse hepatocytes
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were isolated from C57BL/6 wild type (The Jackson Laboratory, Bar Harbor, ME), human MCL-1
transgenic (Ruth W. Craig, Dartmouth University, Hanover, NH), and PkcǇ  mice (The Jackson
Laboratories) by collagenase perfusion, purified by Percoll gradient centrifugation, and plated as
primary cultures as we described previously (48).
Palmitate, stearate, and oleate (Sigma) were individually dissolved in isopropyl
alcohol at a concentration of 80 mM. The concentration of the vehicle, isopropyl alcohol, was 1% in
the final incubations. For all studies employing FFA, the media contained 1% (w/v) bovine serum
albumin to ensure a ratio between bound and unbound FFA analogous to the ratio present in human
plasma (49). The final concentration of fatty acids used ranged from 0 to 800 ǋM based on
concentrations found in human NASH (13, 16, 50). Although these concentrations are similar to total
fasting FFA plasma concentrations found in the pathophysiologic condition of NASH, the
concentrations are elevated compared with each species of FFA present in human plasma.
Cells were incubated for 20 min on ice with lysis buffer (50 mM Tris-HCl, pH 7.4;
1% (w/v) Nonidet P-40; 0.25% (w/v) sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM
phenylmethylsulfonyl fluoride; 1 ǋg/ml aprotinin, leupeptin, and pepstatin; 1 mM Na VO ; 1 mM
NaF) and centrifuged at 14,000 × g for 15 min at 4 °C. Protein concentration was determined by the
Bradford assay (Sigma), and aliquots containing 80 ǋg of protein were electrophoretically resolved by
SDS-PAGE on a pre-cast 12% acrylamide gel (Bio-Rad) and immobilized on nitrocellulose membrane.
Nonspecific binding sites were blocked with 5% (w/v) nonfat dry milk in Tris-buffered saline (20 mM
Tris, 150 mM NaCl, pH 7.4) containing 0.1% (w/v) Tween 20. Blots were incubated with primary
antibodies at room temperature for 2 h or at 4 °C overnight and then, after washing, with secondary
antibodies at room temperature for 1 h.
The following primary antibodies were employed: rabbit polyclonal antibody, which is strongly
reactive to human but not murine Mcl-1 at 1:1000 (sc-819, Santa Cruz Biotechnology, Santa Cruz,
CA); rabbit anti-mouse Mcl-1 (600-401-394, Rockland, Gilbertsville, PA); monoclonal mouse
anti-human PKCǇ (clone 27, Pharmingen); polyclonal rabbit anti-human PKCǇ (2059, Cell Signaling
Technology, Danvers, MA; data not shown); polyclonal rabbit anti-human phospho-Thr  PKCǇ
(9377, Cell Signaling Technology); polyclonal rabbit anti-human PKCį (2058, Cell Signaling
Technology); polyclonal rabbit anti-mouse phospho-Thr  PKCį (9374, Cell Signaling Technology);
polyclonal goat anti-ǃ-actin antibody at 1:2000 (C11, Santa Cruz Biotechnology); and mouse
monoclonal anti-Ǆ-tubulin (T6557, Sigma). Immune complexes were visualized using the Odyssey
infrared imaging system (LI-COR Biosciences, Lincoln, NE) or a chemiluminescent substrate (ECL,
Amersham Biosciences) and Kodak X-Omat film (Eastman Kodak Co.). Quantitation of immune
complexes was performed using Odyssey 3.0 software per the manufacturer's protocol.
Total RNA was isolated from Huh-7
cells using TRIzol (Invitrogen) per the manufacturer's protocol. RNA concentration was estimated by
measuring absorbance at 260 nm using a NanoDrop spectrophotometer (Thermo Fisher Scientific,
Wilmington, DE), and 1 ǋg of total RNA was reverse-transcribed using the SuperScript® III first-
strand synthesis system (Invitrogen) and random hexamer primers per the manufacturer's protocol. A
1.5-ǋl aliquot of a 20-ǋl reverse transcription reaction was subjected to real time PCR analysis. PCR
primers used for human MCL-1 were as follows: forward 5Ļ-AAGCCAATGGGCAGGTCT-3Ļ and reverse
5Ļ-TGTCCAGTTTCCGAAGCAT-3Ļ, which generated an amplicon of 121 bp from the cDNA. The
forward primer is located in exon 1 and the reverse primer in exon 2, and no detectable genomic
product was generated under the PCR conditions employed. Universal ProbeLibrary probe 4 (Roche
Applied Science) bound in the amplicon, and cleavage of the 5Ļ-fluorescein during amplification
generated the fluorescent signal. Commercially available primers for ribosomal 18 S RNA (Ambion,
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Austin, TX) were used for copy controls. The Lightcycler TaqMan master kit (Roche Applied Science)
was employed for all reactions. Quantitative real time PCR using a capillary thermocycler
(LightCycler, Roche Applied Science) was performed as we described previously in detail (21).
Sequential mutagenesis of the established
ubiquitination sites in human Mcl-1 (amino acids 5, 40, 136, 194, and 197) from lysine to arginine
(KR Mcl-1) and mutation of serine at amino acid 159 to alanine (S159A Mcl-1) were performed using
the QuikChange II site-directed mutagenesis kit (Stratagene, Cedar Creek, TX) per the manufacturer's
protocol. S peptide-tagged human Mcl-1 cDNA subcloned into the pcDNA3 vector (Invitrogen), which
has been previously described (51), was used as the template. The entire Mcl-1 insert was sequenced
by automated sequencing to verify that the correct mutation was present and the construct remained
in-frame. The preparation of the S159A mutant has been described previously (51). These plasmids
were prepared for transfection using a plasmid miniprep kit (Bio-Rad). Transfection was performed
with Lipofectamine (Invitrogen). Huh-7 cells were either transfected with an enhanced green
fluorescent protein (GFP) expressing construct alone (pEGFP-N, Clontech) or with GFP plus a
pcDNA3 vector expressing the mutated human Mcl-1 at a 1:2 ratio. Transfected cells were identified
by expression of GFP.
Characteristic morphological changes of apoptosis were assessed by staining
nuclei with 4Ļ,6-diamidino-2-phenylindole dihydrochloride (Sigma) followed by fluorescence
microscopy using excitation and emission wavelengths of 380 and 430 nm, respectively (48, 52).
Caspase-3/7 activity was quantified by measuring rhodamine release from the caspase-3/7 substrate
rhodamine 110, bis(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-L-aspartic acid amide), using the
Apo-ONE™ homogeneous caspase-3/7 kit (Promega Corp., Madison, WI) following the supplier's
instructions.
A previously described construct expressing an shRNA-
targeting Mcl-1 (53) or a human PKCǇ shRNA construct purchased from Sigma were employed to
knock down their respective expression. The constructs were transfected using a standard lipofection
method. Stably transfected Huh-7 clones were selected in medium containing 1200 ǋg/ml G418.
Individual colonies were subcloned and screened for Mcl-1 or PKCǇ expression by immunoblot
analysis.
RNA was extracted from Jurkat and Huh-7 cells using the FastTrack MAG mRNA
isolation kit (Invitrogen) and used for Northern blot analysis. Digoxigenin-labeled probe and
Northern blot examination were performed using the digoxigenin Northern starter kit (Roche Applied
Science) following the manufacturer's instructions. Digoxigenin-labeled probe was created from a
PCR product corresponding to exons 12–14 of the human PKCǇ gene.
Huh-7 cells were stably transfected with S peptide-tagged human Mcl-1 as we have
described previously for other cell types (51). HA-tagged ubiquitin in a pcDNA plasmid was obtained
from Dr. Mark A. McNiven (Mayo Clinic, Rochester, MN) and transiently transfected into the S
peptide Mcl-1-expressing Huh-7 cells. Cells were treated with palmitate (800 ǋM) plus MG-132 (10
mM) for the desired time intervals. S peptide Mcl-1 was affinity-purified from whole cell lysates using
S protein coupled to agarose beads as described previously (51). The affinity-purified protein
complexes were resolved by SDS-PAGE and immobilized on nitrocellulose. Immunoblot analysis was
performed for S peptide and HA.
Huh-7 cells stably transfected with S peptide-tagged Mcl-1 were cultured in
10-cm dishes. After the cells were solubilized in lysis buffer, S peptide-tagged Mcl-1 was recovered on
S protein-agarose as described previously (51). The tagged polypeptide was released into SDS sample
Statistical Analysis
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buffer, resolved by SDS-PAGE, and stained with Coomassie Brilliant Blue (Bio-Rad) in 20% methanol
and 7.5% acetic acid. The Mcl-1 band was excised and subjected to tryptic digestion followed by
quadruple time-of-flight tandem mass spectrometry analysis at the Taplin Biological Mass
Spectrometry Facility, Harvard Medical School.
All data represent at least three independent experiments expressed as the mean ±
S.E. Differences between groups were compared using the two-tailed Student's t test. Analysis of
variance with a Bonferroni test to correct for multiple comparisons was employed when appropriate.
RESULTS
We initially assessed
that if saturated, cytotoxic FFA altered the cellular fate of Mcl-1 in Huh-7 cells. Palmitate (16:0
saturated FFA) induced a rapid decrease of Mcl-1 protein that was apparent within 1 h and maximal
at 4 h (Fig. 1A). Levels of the anti-apoptotic protein Bcl-x , however, were unaltered. Treatment with
the proapoptotic FFA stearate (18:0 saturated FFA) also resulted in a rapid loss of cellular Mcl-1 (
Fig. 1B). In contrast, the nontoxic FFA oleate (18:1 mono-unsaturated FFA) did not significantly
reduce Mcl-1 cellular protein levels (Fig. 1C).
Additional experiments were performed to assess the cause of the Mcl-1 down-regulation. Treatment
with palmitate did not alter steady state levels of MCL-1 mRNA, indicating that FFA are unlikely to
affect either MCL-1 mRNA generation or stability (Fig. 2A). Loss of Mcl-1 was also not simply a
consequence of lipoapoptosis, as the pan-caspase inhibitor Z-VAD-fmk, which blocks FFA-mediated
apoptosis (52), did not prevent loss of cellular Mcl-1 (Fig. 2B, upper and lower panels). Analysis of
replicate immunoblots for palmitate-induced Mcl-1 degradation in the presence or absence of
Z-VAD-fmk revealed no significant difference (p > 0.25) in Mcl-1 levels at any of the analyzed time
points (Fig. 2B, lower panel).
Mcl-1 protein is known to be rapidly turned over in many cell types by a ubiquitin-dependent
proteasome-mediated pathway. Consistent with this concept, the proteasome inhibitor MG-132
blocked loss of cellular Mcl-1 during palmitate treatment (Fig. 2C). To further confirm this
mechanism for Mcl-1 cellular elimination, Huh-7 cells were transiently transfected with a ubiquitin-
resistant Mcl-1 mutant in which lysines 5, 40, 136, 194, and 197 were mutated to arginine (termed KR
Mcl-1), thereby reducing Mcl-1 turnover by the ubiquitin proteasomal pathway (54). Palmitate-
mediated cellular Mcl-1 elimination was attenuated in cells transfected with this ubiquitin-resistant
mutant (Fig. 2D). Collectively, these data suggest that saturated FFA result in Mcl-1 protein
elimination by a ubiquitin-dependent proteasome degradation pathway.
If Mcl-1 degradation contributes to lipoapoptosis, then
transfection with the ubiquitin-resistant mutant should reduce palmitate lipotoxicity. Consistent with
this hypothesis, transfection of Huh-7 cells with KR Mcl-1 not only preserved cellular Mcl-1 levels (
Fig. 2D) but also attenuated palmitate lipotoxicity (Fig. 3, A and B). We next tested the converse
concept, i.e. the ability of Mcl-1 depletion to sensitize cells to lipotoxicity by an otherwise nontoxic
palmitate concentration. Consistent with a pivotal role for Mcl-1 in lipoapoptosis, shRNA-targeted
knockdown of Mcl-1 sensitized cells to otherwise nontoxic concentrations of palmitate (Fig. 3, C and
D).
In additional experiments, we confirmed these observations in primary mouse hepatocytes. In these
cells, palmitate again induced loss of cellular Mcl-1 (Fig. 4A). Hepatocytes isolated from mice
expressing a human MCL-1 transgene had sustained Mcl-1 protein levels after palmitate treatment (
Fig. 4B). As the primary sequence of human and mouse Mcl-1 proteins is not identical (76% identity
and 82% similarity), the preservation of human Mcl-1 suggests that one or more components of the
L
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degradation pathway (potentially the ubiquitin ligase or proteosome itself) exhibits species-specific
preferences. Consistent with the preservation of the hMcl-1 protein levels, these murine hepatocytes
also displayed reduced lipoapoptosis as compared with cells from wild type animals (Fig. 4C). Taken
together, these observations implicate a role for Mcl-1 in regulating lipoapoptosis.
Further experiments were designed to identify the pathway
involved in FFA-induced apoptosis. Phosphorylation of Mcl-1 Ser  by GSK-3ǃ has been shown
previously to accelerate Mcl-1 degradation during growth factor withdrawal via enhanced
ubiquitination (55, 56). However, GSK-3ǃ inhibition did not prevent palmitate-induced degradation
of Mcl-1 (Fig. 5A). In contrast, rottlerin, a cell-permeable pharmacological inhibitor of novel PKC
isozymes, diminished palmitate-induced Mcl-1 degradation (Fig. 5B), raising the possibility that a
novel PKC isoform might contribute to Mcl-1 down-regulation. PKC-dependent ubiquitination of
Mcl-1 was investigated in Huh-7 cells expressing S peptide-tagged Mcl-1 and HA-tagged ubiquitin. To
facilitate the detection of ubiquitinated Mcl-1, the proteasome inhibitor MG-132 was employed.
Ubiquitinated Mcl-1 was detected in Huh-7 cells treated with palmitate, although cells co-treated
with rottlerin displayed decreased ubiquitinated Mcl-1 signal, consistent with PKC-dependent
ubiquitination (Fig. 5C).
Members of the novel PKC isozymes contain autoinhibitory domains that fold into the substrate-
binding site within the catalytic domain to prevent substrate recognition. Phosphorylation of the
autoinhibitory domain results in a conformational change, permitting recognition of substrates by
this enzyme (57). Palmitate induces rapid Thr  phosphorylation within this autoinhibitory domain,
consistent with PCKǇ activation (Fig. 6A). In contrast, PKCį was not strongly phosphorylated at
Thr  within its autoinhibitory domain following exposure to palmitate (Fig. 6B). Of note, blotting
with either the Thr  phospho-specific PKCǇ or total PKCǇ antiserum displayed a single polypeptide
of 55 kDa (also observed using an unrelated polyclonal anti-PKCǇ antibody, data not shown),
although the expected molecular mass of PKCǇ has been reported to be 79 kDa, which we observed
with whole cell extracts from Jurkat cells (supplemental Fig.). Based on this observation, we posited
that hepatocytes might express a unique PKCǇ isoform. Consistent with this possibility, Northern blot
analysis demonstrated a 1.9-kb band in Huh-7 cells compared with the 2.8-kb band observed in
Jurkat cells, suggesting that an alternative splice variant is the predominant PKCǇ isoform in
hepatocytes (Fig. 6C). Exploration of the mRNA by reverse transcription followed by long distance
PCR demonstrated exons 2–15 in both Jurkat and Huh-7 cells, although a product was identified
using primers in exons 2–18 only in Jurkat but not Huh-7 cells (supplemental Fig.). Likely the mRNA
is alternatively spliced at or near the 3Ļ-terminal exon.
To explore the function of this PKCǇ isoform in lipoapoptosis, we knocked down its expression using
shRNA that targeted nucleotides within the catalytic domain of the enzyme. This shRNA construct
successfully knocked down expression of the 55-kDa PKCǇ isoform (Fig. 7A), further confirming the
immunoreactive band at 55 kDa represents PKCǇ. shRNA-targeted knockdown of PCKǇ prevented
palmitate-induced degradation of Mcl-1 and actually resulted in an increased level of this
anti-apoptotic protein (Fig. 7B). Retention of Mcl-1 during palmitate treatment was also observed in
primary mouse hepatocytes from PkcǇ  animals (Fig. 7C). Taken together, these data implicated
PKCǇ in the degradation of Mcl-1 by saturated FFA.
If PKCǇ inhibition
attenuates Mcl-1 loss, then PKCǇ inhibition should also ameliorate lipoapoptosis. Consistent with
this prediction, inhibition of PKCǇ activity with rottlerin or reduction of PKCǇ by shRNA reduced
lipotoxicity by palmitate in Huh-7 cells (Fig. 8, A and B). Moreover, palmitate-induced apoptosis was
significantly reduced in primary hepatocytes from PkcǇ  versus wild type mice (Fig. 8C). Thus,
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Ser  Phosphorylation Contributes to Mcl-1 Degradation and Lipoapoptosis by Palmitate
inhibition of PKCǇ activity or expression not only maintains cellular Mcl-1 levels upon palmitate
challenge, but also mitigates lipoapoptosis.
To further explore the
role of PKCǇ in Mcl-1 degradation, we next determined whether Mcl-1 phosphorylation required
PKCǇ catalytic activity. For these studies we employed Huh-7 cells stably transfected with an S
peptide-tagged Mcl-1 to facilitate affinity purification of Mcl-1. Huh-7 cells stably expressing S
peptide-tagged Mcl-1 were treated with palmitate with or without rottlerin, and Mcl-1 was affinity-
purified and analyzed by mass spectrometry. Ser , a previously described phosphorylation site of
Mcl-1, was found to be phosphorylated in palmitate-treated cells but not in cells treated with
palmitate plus rottlerin, suggesting PKCǇ-dependent Mcl-1 Ser  phosphorylation.
The potential Mcl-1 Ser  phosphorylation following PKCǇ activation was further investigated by
antiserum specific for Mcl-1 phosphorylated at both Ser  and Thr . To confirm the specificity of
this antiserum, we expressed wild type, S159A, and T163A mutant Mcl-1 in Huh-7 cells followed by S
protein-based affinity purification and immunoblot analysis. Phosphorylated wild type Mcl-1 was
readily identified, whereas substitution of either Ser  or Thr  with alanine prevented recognition
by this phospho-specific antiserum (Fig. 9A). There was a slight increase in phosphorylated Mcl-1
from cells treated with palmitate (Fig. 9A, 4th lane) compared with vehicle (1st lane). To determine
whether phosphorylation was dependent upon PKCǇ activity, we incubated cells in the presence or
absence of rottlerin, with or without palmitate. Inhibition of novel PKC activity decreased the
phospho-Mcl-1 signal (Fig. 9B).
We reasoned that blocking phosphorylation of Mcl-1 at Ser  would prevent the degradation of Mcl-1
and promote survival upon palmitate treatment. Mutation of Ser  to alanine results in decreased
palmitate-induced Mcl-1 degradation (Fig. 9C) and lipoapoptosis (Fig. 9D). Thus, whether PKCǇ
directly or indirectly phosphorylates Mcl-1 at Ser , phosphorylation at this site regulates Mcl-1
turnover and cell survival during exposure to palmitate.
DISCUSSION
Results of this study provide new insight into the mechanism of FFA-induced lipoapoptosis by
showing in Huh-7 cells and primary murine hepatocytes the following: (i) the saturated FFA
palmitate and stearate, but not the unsaturated FFA oleate, induce loss of cellular Mcl-1 protein by a
proteasome-dependent pathway; (ii) inhibition of Mcl-1 degradation attenuates apoptosis by
saturated FFA; and (iii) Mcl-1 degradation and apoptosis by saturated FFA appear to be mediated, in
part, by PKCǇ. Each of these results is discussed in greater detail below.
In the multiple model systems described here, treatment of liver-derived cells with saturated FFA
results in rapid loss of cellular Mcl-1 protein. The observations that saturated FFA such as palmitate
and stearate, but not the unsaturated FFA oleate, result in Mcl-1 loss are consistent with prior
observations regarding the specificity of these FFA in mediating lipoapoptosis (52, 58). Although
Mcl-1 regulation is multifaceted (reviewed in Ref. 36), our data suggest that saturated FFA induce
Mcl-1 degradation by a ubiquitin-dependent proteasome degradation pathway. For example, loss of
Mcl-1 was attenuated by the proteasome inhibitor MG-132 and, more importantly, by mutation of the
five key lysine residues within its proline-, glutamic acid-, serine-, and threonine-rich sequence that
are necessary for ubiquitination. In addition ubiquitinated Mcl-1 was detected in palmitate-treated
cells. Two ubiquitin-protein isopeptide ligases, ǃ-TrCP and Mule, have been reported to ubiquitinate
this polypeptide promoting its recognition and rapid degradation by the proteasome (54, 59).
Although we cannot rule out the possibility that saturated FFA regulate the activity of these ubiquitin-
protein isopeptide ligase, our data suggest that the major contributor to FFA-induced Mcl-1
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down-regulation is a direct post-translational modification of Mcl-1 by a PKCǇ-mediated pathway,
thereby rendering it susceptible to ubiquitin-protein isopeptide ligase ubiquitination (see below).
Several observations suggest loss of cellular Mcl-1 is not simply a consequence of cell death but rather
contributes to FFA cytotoxicity. First, a pan-caspase inhibitor that prevents cell death (52) did not
avert loss of cellular Mcl-1. We also did not observe Mcl-1 degradation products by immunoblot
analysis as has been identified in processes associated with caspase-mediated Mcl-1 cleavage (60).
Second, expression of a ubiquitin-resistant mutant, which undergoes limited degradation in response
to saturated FFA, attenuates cell death. Finally, shRNA-induced reduction in Mcl-1 levels further
sensitizes the cells to lipotoxicity. These observations are consistent with published data indicating
that cellular elimination of Mcl-1 is a pivotal step in several apoptotic pathways (34, 35). Prior studies
on the regulation of hepatocyte lipoapoptosis by Bcl-2 proteins have focused on the role of
proapoptotic members of this family, especially Bim-mediated activation of Bax (52). This study
extends these observations by demonstrating a key role for the anti-apoptotic protein Mcl-1 in
hepatocyte lipoapoptosis. Mcl-1 may attenuate apoptosis by binding to and sequestering Bim, thereby
preventing its activation of Bax (24, 61, 62). Thus, a broader picture of lipoapoptosis by saturated FFA
is emerging where loss of Mcl-1 likely facilitates Bim activation of Bax, which in turn triggers the
mitochondrial cell death pathway.
Our observations suggest that the novel PKC isoform PKCǇ promotes Mcl-1 degradation by cytotoxic
FFA in hepatocytes. Pharmacologic inhibition of PKCǇ with rottlerin, inhibition of PKCǇ protein
expression by targeted shRNA, and genetic deletion of PkcǇ all reduced loss of Mcl-1 and
lipoapoptosis by palmitate. Interestingly, the PKCǇ expressed in hepatocytes migrates significantly
faster on gels than that in Jurkat cells. Evidence that the 55-kDa band in hepatocytes represents
PKCǇ includes recognition of a band of the same molecular weight by an unrelated PKCǇ antiserum
(phospho-PKCǇ epitope), as well as modulation of expression by an shRNA targeting PKCǇ. Northern
blot and PCR analyses suggest that a smaller alternative splice form is responsible for the polypeptide
identified on SDS-PAGE. The faster migrating PKCǇ protein and reduced size of mRNA have not
previously been described and may well be liver-specific splice variants, raising the possibility of
unique regulation of this kinase in liver.
Although PKCǇ has been implicated in apoptosis of Jurkat, neuroblastoma, and myeloid leukemia
cells (46, 47), its effects on cellular Mcl-1 protein levels have not been reported previously. The
present data suggest that PKCǇ activity contributes to Mcl-1 Ser  phosphorylation. Mcl-1
phosphorylation at this residue has been shown previously to prime Mcl-1 for ubiquitin-protein
isopeptide ligase-directed ubiquitination and subsequent proteasome degradation (55). Although
GSK-3ǃ can phosphorylate Mcl-1 at Ser , a GSK-3ǃ inhibitor did not prevent Mcl-1 degradation by
palmitate treatment. More importantly, as identified by mass spectrometry, the novel PKC inhibitor
rottlerin blocked Mcl-1 Ser  phosphorylation and ubiquitination during exposure to palmitate.
These composite observations suggest that PKCǇ may directly phosphorylate Mcl-1 at Ser , an
interpretation supported by the in silico observation that this site is a PKC consensus phosphorylation
site (Netphos 2.0).
In summary, regulation of the mitochondrial death pathway by Bcl-2 proteins is a complex and
hierarchal process that displays cell type- and stimulus-specific pathways. Lipoapoptosis appears to
involve all three subsets of Bcl-2 proteins. Expression of the BH3-only protein Bim, which promotes
Bax activation, is increased by the transcription factor FoxO3a (21, 52). This work extends these
observations by also implicating PKCǇ-driven Mcl-1 elimination as a critical event in this cytotoxic
process. Consistent with activation of a complex cytotoxic network, we note that inhibition of Bim
expression or PKCǇ activation individually only partially ameliorates hepatocyte lipotoxicity. Thus,
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inhibition of any single component is not sufficient to totally abrogate lipoapoptosis. Other
overlapping signaling processes may also contribute to saturated FFA-mediated hepatocyte
cytotoxicity. The optimal therapeutic strategy to minimize hepatic lipotoxicity will require knowledge
of the composite cytotoxic network induced by FFA. Once these networks are elucidated, therapeutic
strategies can be developed to minimize liver damage in human fatty liver diseases.
Supplementary Material
Supplemental Data:
This work was supported, in whole or in part, by National Institutes of Health Grants R01 DK41876 (to G. J. G.), T32
07198 (to H. C. M.), K01 DK79875 (to J. L. M.), R01 CA69008 (to S. H. K.), and the optical microscopy core of
P309K 84567. This work was also supported by the Mayo Foundation.
The on-line version of this article (available at http://www.jbc.org) contains a supplemental figure.
The abbreviations used are:
NASH nonalcoholic steatohepatitis
FFA free fatty acid
GFP green fluorescent protein
GSK-3ȕ glycogen synthase kinase-3ȕ
KR Mcl-1 lysine to arginine ubiquitin-resistant Mcl-1 mutant
PEST sequences rich in proline, glutamic acid, serine, threonine
PKC protein kinase C
shRNA short hairpin RNA
Z- benzyloxycarbonyl-
fmk fluoromethyl ketone
HA hemagglutinin.
REFERENCES
1. Browning J. D., Szczepaniak L. S., Dobbins R., Nuremberg P., Horton J. D., Cohen J. C., Grundy S.
M., Hobbs H. H. (2004) Hepatology 40, 1387–1395. [PubMed: 15565570]
2. Adams L. A., Lymp J. F., St Sauver J., Sanderson S. O., Lindor K. D., Feldstein A., Angulo P. (2005)
Gastroenterology 129, 113–121. [PubMed: 16012941]
3. Ekstedt M., Franzén L. E., Mathiesen U. L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S.
(2006) Hepatology 44, 865–873. [PubMed: 17006923]
4. Ratziu V., Poynard T. (2006) Hepatology 44, 802–805. [PubMed: 17006914]
5. Chavez-Tapia N. C., Mendez-Sanchez N., Uribe M. (2006) Ann. Intern. Med. 144, 379–380.
[PubMed: 16520485]
6. Angulo P. (2002) N. Engl. J. Med. 346, 1221–1231. [PubMed: 11961152]
7. Parekh S., Anania F. A. (2007) Gastroenterology 132, 2191–2207. [PubMed: 17498512]
8. Donnelly K. L., Smith C. I., Schwarzenberg S. J., Jessurun J., Boldt M. D., Parks E. J. (2005) J.
Clin. Invest. 115, 1343–1351. [PMCID: PMC1087172] [PubMed: 15864352]
9. Doege H., Grimm D., Falcon A., Tsang B., Storm T. A., Xu H., Ortegon A. M., Kazantzis M., Kay M.
A., Stahl A. (2008) J. Biol. Chem. 283, 22186–22192. [PMCID: PMC2494916] [PubMed: 18524776]
*
2
10. Zhou J., Febbraio M., Wada T., Zhai Y., Kuruba R., He J., Lee J. H., Khadem S., Ren S., Li S.,
Silverstein R. L., Xie W. (2008) Gastroenterology 134, 556–567. [PubMed: 18242221]
11. Listenberger L. L., Han X., Lewis S. E., Cases S., Farese R. V., Jr., Ory D. S., Schaffer J. E. (2003)
Proc. Natl. Acad. Sci. U.S.A. 100, 3077–3082. [PMCID: PMC152249] [PubMed: 12629214]
12. Yamaguchi K., Yang L., McCall S., Huang J., Yu X. X., Pandey S. K., Bhanot S., Monia B. P., Li Y.
X., Diehl A. M. (2007) Hepatology 45, 1366–1374. [PubMed: 17476695]
13. Nehra V., Angulo P., Buchman A. L., Lindor K. D. (2001) Dig. Dis. Sci. 46, 2347–2352.
[PubMed: 11713934]
14. de Almeida I. T., Cortez-Pinto H., Fidalgo G., Rodrigues D., Camilo M. E. (2002) Clin. Nutr. 21,
219–223. [PubMed: 12127930]
15. Araya J., Rodrigo R., Videla L. A., Thielemann L., Orellana M., Pettinelli P., Poniachik J. (2004)
Clin. Sci. 106, 635–643. [PubMed: 14720121]
16. Belfort R., Harrison S. A., Brown K., Darland C., Finch J., Hardies J., Balas B., Gastaldelli A., Tio
F., Pulcini J., Berria R., Ma J. Z., Dwivedi S., Havranek R., Fincke C., DeFronzo R., Bannayan G. A.,
Schenker S., Cusi K. (2006) N. Engl. J. Med. 355, 2297–2307. [PubMed: 17135584]
17. Larter C. Z., Yeh M. M., Haigh W. G., Williams J., Brown S., Bell-Anderson K. S., Lee S. P., Farrell
G. C. (2008) J. Hepatol. 48, 638–647. [PubMed: 18280001]
18. Gentile C. L., Pagliassotti M. J. (2008) J. Nutr. Biochem. 19, 567–576. [PMCID: PMC2551556]
[PubMed: 18430557]
19. Wang D., Wei Y., Pagliassotti M. J. (2006) Endocrinology 147, 943–951. [PubMed: 16269465]
20. Malhi H., Barreyro F. J., Isomoto H., Bronk S. F., Gores G. J. (2007) Gut 56, 1124–1131.
[PMCID: PMC1955518] [PubMed: 17470478]
21. Barreyro F. J., Kobayashi S., Bronk S. F., Werneburg N. W., Malhi H., Gores G. J. (2007) J. Biol.
Chem. 282, 27141–27154. [PubMed: 17626006]
22. Feldstein A. E., Canbay A., Angulo P., Taniai M., Burgart L. J., Lindor K. D., Gores G. J. (2003)
Gastroenterology 125, 437–443. [PubMed: 12891546]
23. Wieckowska A., Zein N. N., Yerian L. M., Lopez A. R., McCullough A. J., Feldstein A. E. (2006)
Hepatology 44, 27–33. [PubMed: 16799979]
24. Youle R. J., Strasser A. (2008) Nat. Rev. Mol. Cell Biol. 9, 47–59. [PubMed: 18097445]
25. Tzung S. P., Fausto N., Hockenbery D. M. (1997) Am. J. Pathol. 150, 1985–1995.
[PMCID: PMC1858315] [PubMed: 9176392]
26. Print C. G., Loveland K. L., Gibson L., Meehan T., Stylianou A., Wreford N., de Kretser D., Metcalf
D., Köntgen F., Adams J. M., Cory S. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 12424–12431.
[PMCID: PMC22847] [PubMed: 9770502]
27. Ross A. J., Waymire K. G., Moss J. E., Parlow A. F., Skinner M. K., Russell L. D., MacGregor G. R.
(1998) Nat. Genet. 18, 251–256. [PubMed: 9500547]
28. Hamasaki A., Sendo F., Nakayama K., Ishida N., Negishi I., Nakayama K., Hatakeyama S. (1998)
J. Exp. Med. 188, 1985–1992. [PMCID: PMC2212378] [PubMed: 9841913]
29. Takehara T., Tatsumi T., Suzuki T., Rucker E. B., 3rd, Hennighausen L., Jinushi M., Miyagi T.,
Kanazawa Y., Hayashi N. (2004) Gastroenterology 127, 1189–1197. [PubMed: 15480996]
30. Vick B., Weber A., Urbanik T., Maass T., Teufel A., Krammer P. H., Opferman J. T., Schuchmann
M., Galle P. R., Schulze-Bergkamen H. (2009) Hepatology 49, 627–636. [PMCID: PMC2753874]
[PubMed: 19127517]
31. Schulze-Bergkamen H., Brenner D., Krueger A., Suess D., Fas S. C., Frey C. R., Dax A., Zink D.,
Büchler P., Müller M., Krammer P. H. (2004) Hepatology 39, 645–654. [PubMed: 14999683]
32. Kahraman A., Mott J. L., Bronk S. F., Werneburg N. W., Barreyro F. J., Guicciardi M. E., Akazawa
Y., Braley K., Craig R. W., Gores G. J. (2009) Dig. Dis. Sci. 54, 1908–1917. [PMCID: PMC2879585]
[PubMed: 19051025]
33. Kodama Y., Taura K., Miura K., Schnabl B., Osawa Y., Brenner D. A. (2009) Gastroenterology 136,
1423–1434. [PubMed: 19249395]
34. Nijhawan D., Fang M., Traer E., Zhong Q., Gao W., Du F., Wang X. (2003) Genes Dev. 17,
1475–1486. [PMCID: PMC196078] [PubMed: 12783855]
35. Cuconati A., Mukherjee C., Perez D., White E. (2003) Genes Dev. 17, 2922–2932.
[PMCID: PMC289151] [PubMed: 14633975]
36. Warr M. R., Shore G. C. (2008) Curr. Mol. Med. 8, 138–147. [PubMed: 18336294]
37. Solinas G., Naugler W., Galimi F., Lee M. S., Karin M. (2006) Proc. Natl. Acad. Sci. U.S.A. 103,
16454–16459. [PMCID: PMC1637603] [PubMed: 17050683]
38. Schenk S., Saberi M., Olefsky J. M. (2008) J. Clin. Invest. 118, 2992–3002.
[PMCID: PMC2522344] [PubMed: 18769626]
39. Itani S. I., Ruderman N. B., Schmieder F., Boden G. (2002) Diabetes 51, 2005–2011.
[PubMed: 12086926]
40. Timmers S., Schrauwen P., de Vogel J. (2008) Physiol. Behav. 94, 242–251. [PubMed: 18207474]
41. Yu C., Chen Y., Cline G. W., Zhang D., Zong H., Wang Y., Bergeron R., Kim J. K., Cushman S. W.,
Cooney G. J., Atcheson B., White M. F., Kraegen E. W., Shulman G. I. (2002) J. Biol. Chem. 277,
50230–50236. [PubMed: 12006582]
42. Puri P., Baillie R. A., Wiest M. M., Mirshahi F., Choudhury J., Cheung O., Sargeant C., Contos M.
J., Sanyal A. J. (2007) Hepatology 46, 1081–1090. [PubMed: 17654743]
43. Sakaki K., Wu J., Kaufman R. J. (2008) J. Biol. Chem. 283, 15370–15380.
[PMCID: PMC2397484] [PubMed: 18356160]
44. Kim J. K., Fillmore J. J., Sunshine M. J., Albrecht B., Higashimori T., Kim D. W., Liu Z. X., Soos T.
J., Cline G. W., O'Brien W. R., Littman D. R., Shulman G. I. (2004) J. Clin. Invest. 114, 823–827.
[PMCID: PMC516267] [PubMed: 15372106]
45. Savage D. B., Petersen K. F., Shulman G. I. (2007) Physiol. Rev. 87, 507–520.
[PMCID: PMC2995548] [PubMed: 17429039]
46. Schultz A., Jönsson J. I., Larsson C. (2003) Cell Death Differ. 10, 662–675. [PubMed: 12761575]
47. Datta R., Kojima H., Yoshida K., Kufe D. (1997) J. Biol. Chem. 272, 20317–20320.
[PubMed: 9252332]
48. Faubion W. A., Guicciardi M. E., Miyoshi H., Bronk S. F., Roberts P. J., Svingen P. A., Kaufmann
S. H., Gores G. J. (1999) J. Clin. Invest. 103, 137–145. [PMCID: PMC407865] [PubMed: 9884343]
49. Richieri G. V., Kleinfeld A. M. (1995) J. Lipid Res. 36, 229–240. [PubMed: 7751810]
50. Sanyal A. J., Campbell-Sargent C., Mirshahi F., Rizzo W. B., Contos M. J., Sterling R. K., Luketic
V. A., Shiffman M. L., Clore J. N. (2001) Gastroenterology 120, 1183–1192. [PubMed: 11266382]
51. Kobayashi S., Lee S. H., Meng X. W., Mott J. L., Bronk S. F., Werneburg N. W., Craig R. W.,
Kaufmann S. H., Gores G. J. (2007) J. Biol. Chem. 282, 18407–18417. [PubMed: 17463001]
52. Malhi H., Bronk S. F., Werneburg N. W., Gores G. J. (2006) J. Biol. Chem. 281, 12093–12101.
[PubMed: 16505490]
53. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S. F., Farrugia D. J., Kaufmann S. H.,
Gores G. J. (2004) Cancer Res. 64, 3517–3524. [PubMed: 15150106]
54. Zhong Q., Gao W., Du F., Wang X. (2005) Cell 121, 1085–1095. [PubMed: 15989957]
55. Maurer U., Charvet C., Wagman A. S., Dejardin E., Green D. R. (2006) Mol. Cell 21, 749–760.
[PubMed: 16543145]
56. Zhao Y., Altman B. J., Coloff J. L., Herman C. E., Jacobs S. R., Wieman H. L., Wofford J. A.,
Dimascio L. N., Ilkayeva O., Kelekar A., Reya T., Rathmell J. C. (2007) Mol. Cell. Biol. 27,
4328–4339. [PMCID: PMC1900055] [PubMed: 17371841]
57. Liu Y., Graham C., Li A., Fisher R. J., Shaw S. (2002) Biochem. J. 361, 255–265.
[PMCID: PMC1222305] [PubMed: 11772397]
58. Wei Y., Wang D., Topczewski F., Pagliassotti M. J. (2006) Am. J. Physiol. Endocrinol. Metab. 291,
E275–E281. [PubMed: 16492686]
59. Ding Q., He X., Hsu J. M., Xia W., Chen C. T., Li L. Y., Lee D. F., Liu J. C., Zhong Q., Wang X.,
Hung M. C. (2007) Mol. Cell. Biol. 27, 4006–4017. [PMCID: PMC1900029] [PubMed: 17387146]
60. Han J., Goldstein L. A., Gastman B. R., Froelich C. J., Yin X. M., Rabinowich H. (2004) J. Biol.
Chem. 279, 22020–22029. [PubMed: 15014070]
61. Meng X. W., Lee S. H., Dai H., Loegering D., Yu C., Flatten K., Schneider P., Dai N. T., Kumar S.
K., Smith B. D., Karp J. E., Adjei A. A., Kaufmann S. H. (2007) J. Biol. Chem. 282, 29831–29846.
[PubMed: 17698840]
62. Gavathiotis E., Suzuki M., Davis M. L., Pitter K., Bird G. H., Katz S. G., Tu H. C., Kim H., Cheng E.
H., Tjandra N., Walensky L. D. (2008) Nature 455, 1076–1081. [PMCID: PMC2597110]
[PubMed: 18948948]
Figures and Tables
FIGURE 1.
Mcl-1 protein levels decrease in Huh-7 cells in response to treatment with saturated free fatty acids.
Immunoblot of whole cell extracts was obtained from Huh-7 cells treated with 800 ǋM palmitate (A), 600 ǋM
stearate (B), or 800 ǋM oleate (C) for the indicated times. Endogenous human Mcl-1 in Huh-7 cells consistently
migrated as a doublet of 42 kDa. Immunoblot analysis was performed for the proteins of interest, Mcl-1 (sc-819),
Bcl-x , and ǃ-actin, a control for protein loading.L
FIGURE 2.
Palmitate destabilizes Mcl-1 protein and not mRNA. A, palmitate does not alter steady state Mcl-1 mRNA
levels. Mcl-1 mRNA levels were measured by quantitative real time PCR performed on cDNA from Huh-7 cells
treated with 800 ǋM palmitate for the time intervals indicated. Ribosomal 18 S RNA was used as a copy control. Each
point is the absolute number of copies of Mcl-1 mRNA divided by the number of copies of 18 S RNA determined by
comparison with known standards. B, caspase inhibition does not prevent palmitate-induced loss of Mcl-1 protein
level. Huh-7 cells were incubated in the presence of 800 ǋM palmitate plus 50 ǋM Z-VAD-fmk for the time intervals
indicated. Whole cell extracts were obtained, and proteins were resolved by SDS-PAGE. Immunoblot analysis was
performed for Mcl-1 and, as a control for protein loading, ǃ-actin. C, MG-132, a proteasome inhibitor, blocks
palmitate-induced loss of cellular Mcl-1 protein. Huh-7 cells were incubated in the presence of 800 ǋM palmitate
plus 10 ǋM MG-132. At the time intervals indicated, total protein was isolated for immunoblot analysis. D,
proteasome-resistant Mcl-1 mutant is resistant to cellular degradation. Huh-7 cells were transiently transfected with
a construct expressing a human Mcl-1 with mutations (lysine to arginine) of five established ubiquitination sites
(KR Mcl-1). Twenty four h after transfection, cells were treated with 800 ǋM palmitate. Immunoblot analysis for
Mcl-1 was performed on whole cell extracts obtained at the time intervals indicated. In contrast to endogenous
Mcl-1, KR Mcl-1 migrated as a single 42-kDa band.
FIGURE 3.
Overexpression of a ubiquitin-resistant Mcl-1 mutant (KR Mcl-1) protects Huh-7 cells from
lipoapoptosis, and targeted Mcl-1 knockdown sensitizes cells to palmitate-induced lipoapoptosis. A
and B, Huh-7 cells were transiently transfected with a plasmid expressing KR Mcl-1 or GFP as control. Twenty four h
following transfection, the cells were treated with 800 ǋM palmitate for 16 h at 37 °C. Apoptosis was quantified
morphologically (A) as described under “Experimental Procedures” or biochemically (B) by measuring caspase-3/7
activity. *, statistically significant difference (p < 0.01) compared with GFP vehicle cells; **, statistically significant
difference (p < 0.01) compared with GFP palmitate cells. C, Mcl-1 knockdown was performed by stable transfection
of Huh-7 cells with a plasmid encoding shRNA directed to Mcl-1. Efficiency of the targeted knockdown of Mcl-1 was
established by immunoblot analysis of whole cell extracts. D, knockdown of Mcl-1 increases sensitivity of Huh-7
cells to lipoapoptosis by palmitate. Huh-7 cells and Huh-7 cells stably transfected with shRNA targeted against Mcl-1
(shMcl-1) were incubated with 400 ǋM palmitic acid for 16 h. Apoptosis was quantified morphologically (C) and
biochemically (D) by measuring caspase-3/7 activity. **, statistically significant difference (p < 0.01) for palmitate-
treated shMcl-1 cells versus the palmitate-treated parental cell line.
FIGURE 4.
Primary hepatocytes isolated from mice overexpressing human Mcl-1 are resistant to palmitate-
induced loss of Mcl-1 and lipoapoptosis. A, primary murine hepatocytes were isolated from wild type C57BL/6
mice and cultured overnight. Cells were treated with 400 ǋM palmitate for the time intervals indicated, and whole
cell extracts were procured. Immunoblot analysis was performed for murine Mcl-1 (Rockland) and ǃ-actin. Murine
Mcl-1 migrated as a doublet with a dominant band of ˇ37 kDa. B, primary murine hepatocytes were obtained from
C57BL/6 mice transgenic for human MCL-1. Studies were performed as described in A with Mcl-1 immunoblot using
sc-819 anti-human Mcl-1. C, primary mouse hepatocytes from C57BL/6, wild type (WT), and transgenic mice for
human MCL-1 (Mcl-1 Tg) were treated with 400 ǋM palmitate for 8 h. Apoptosis was quantified based on nuclear
morphology. *, statistically significant difference (p < 0.01) compared with vehicle-treated wild type cells; **,
statistically significant difference (p < 0.001) compared with palmitate-treated wild type cells.
FIGURE 5.

Inhibition of PKCǇ, a novel PKC, blocks Mcl-1 degradation by palmitate. Huh-7 cells were incubated in the
presence of 800 ǋM palmitate plus 3 ǋM GSK-3ǃ inhibitor IX (A) or 10 ǋM of the novel PKC inhibitor rottlerin (B). At
the time intervals indicated, whole cell extracts were prepared for immunoblot analysis. C, ubiquitination of Mcl-1 is
dependent on novel PKC activity. Whole cell extracts were prepared from Huh-7 cells stably expressing HA-tagged
ubiquitin that were treated with 800 ǋM palmitate and the proteasome inhibitor MG-132 for 8 h either with or
without the PKCǇ inhibitor rottlerin. Affinity pulldown (PD) was performed for S-tagged (S-tag) Mcl-1 using protein
S-agarose followed by immunoblot (IB) analysis of ubiquitin with anti-HA peptide tag antibody.
FIGURE 6.
Palmitate induces phosphorylation of PKCǇ but not PKCį. A, Huh-7 cells were incubated in the presence of
800 ǋM palmitate over the time intervals indicated. Whole cell lysates were subjected to immunoblot analysis for
phospho-Thr  PKCǇ and total PKCǇ or (B) phospho-Thr  PKCį and total PKCį. Immunoblots were also probed
for Į-tubulin or ǃ-actin as loading controls. C, Northern blot analysis demonstrates expression of a PKCǇ mRNA in
Huh-7 cells that is smaller than the transcript in Jurkat cells.
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FIGURE 7.
shRNA-targeted knockdown of PKCǇ prevents palmitate-induced loss of Mcl-1. A, immunoblot analysis
for PKCǇ using whole cell extracts from Huh-7 cells stably transfected with empty vector expression construct as a
control and cells stably transfected with the PKCǇ-targeted shRNA. B, stable cell lines (as described in A) were
incubated with 800 ǋM palmitate over 6 h. Immunoblot analysis was performed on whole cell extracts for Mcl-1 and
ǃ-actin as a control for protein loading. C, hepatocytes from PkcǇ  mice maintain Mcl-1 protein levels following
palmitate treatment. Primary murine hepatocytes from PkcǇ knock-out mice were treated with palmitate 400 ǋM. At
desired time intervals, whole cell lysates were prepared and blotted for Mcl-1 and actin (cf. Fig. 4A). In primary
hepatocytes from PkcǇ  mice, actin was detected as a doublet, possibly due to detection of both ǃ and Ǆ isoforms.
í/í
í/í
FIGURE 8.
Inhibition, shRNA-mediated knockdown, and genetic deletion of PkcǇ reduce lipoapoptosis. A, Huh-7
cells were treated with the novel PKC inhibitor rottlerin (10 ǋM) beginning 30 min prior to the addition of 800 ǋM
palmitate. After 16 h of incubation, apoptosis was quantified by characteristic nuclear morphologic changes. B,
Huh-7 cells were stably transfected with an shRNA targeting PKCǇ or the empty expression construct (Huh-7; see
Fig. 7). After 16 h of incubation with 800 ǋM palmitate, apoptosis was quantified by nuclear morphology. C,
apoptosis was also quantified in primary murine hepatocytes from wild type and PkcǇ  mice at 8 h following
addition of 400 ǋM palmitate. *, statistically significant difference (p < 0.01) compared with vehicle-treated cells; **,
statistically significant difference (p < 0.01) compared with palmitate-treated cells in the absence of rottlerin.
í/í
FIGURE 9.
Mcl-1 Ser  is phosphorylated in a PKC-dependent manner, and S159A mutation decreases palmitate-
induced Mcl-1 degradation and apoptosis. A, affinity-purified S peptide-tagged Mcl-1 from Huh-7 cells treated
159
with vehicle or 800 ǋM palmitate was blotted using antiserum specific for phosphorylation at Ser /Thr .
Mutation of either site to Ala prevents detection with this antibody. PD, pulldown; IB, immunoblot; WT, wild type.
B, whole cell lysates of Huh-7 cells treated with MG-132 as well as rottlerin (Rott) (10 ǋM) and palmitate (PA) (800
ǋM) as indicated were blotted with anti-phospho-Mcl-1 or total Mcl-1. Veh, vehicle. The proteasome inhibitor
MG-132 was included to prevent degradation and facilitate detection of phosphorylated Mcl-1. C, Huh-7 cells were
stably transfected with a construct expressing either S peptide-tagged wild type Mcl-1 (left) or S159A Mcl-1 (right).
The stable transfectants were treated with palmitate (800 ǋM) for the indicated time and then subjected to
immunoblot analysis with anti-S peptide antibody. The ratio of intensities of S peptide-tagged Mcl-1 to ǃ-actin is
shown. S peptide-tagged human Mcl-1 migrates as a single band of 42 kDa. D, stable transfectants were treated with
800 ǋM palmitate for 16 h, and apoptosis was quantitated by characteristic morphologic features. *, statistically
significant difference (p < 0.01) compared with vehicle-treated cells transfected with wild type Mcl-1;**, statistically
significant difference (p < 0.001) compared with palmitate-treated cells transfected with wild type Mcl-1.
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